PMID- 32853821
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 2213-2201 (Electronic)
VI  - 9
IP  - 1
DP  - 2021 Jan
TI  - Psychometric Properties of the Asthma Symptom Index in Patients with Severe 
      Asthma.
PG  - 400-409.e1
LID - S2213-2198(20)30835-7 [pii]
LID - 10.1016/j.jaip.2020.08.019 [doi]
AB  - BACKGROUND: Evaluation of symptoms is essential in asthma clinical research. 
      Daily symptom diaries require once- or twice-daily recording, making them less 
      suited to real-world use. A modified version of the established Asthma Symptom 
      Utility Index (ASUI) that includes symptom attributes (Asthma Symptom Index 
      [ASI]) was developed as a less-burdensome measure of asthma symptoms. OBJECTIVE: 
      To evaluate the ASI and replicate ASUI psychometric properties, including 
      validity, reliability, responsiveness, and minimal clinically important 
      difference (MCID) estimation in patients >/=12 years of age with severe asthma. 
      METHODS: Patients from a randomized trial (MUSCA [n = 497]) and a cross-sectional 
      study (IDEAL [n = 721]) were analyzed post hoc. Demographic information, 
      spirometry, ASI and ASUI scores, and other patient-reported outcome measures such 
      as Asthma Control Questionnaire (ACQ-5) and St George's Respiratory Questionnaire 
      (SGRQ) at baseline and during follow-up (MUSCA only) were obtained. RESULTS: 
      Internal consistency reliability and test-retest reliability were considered good 
      (>0.70 [Cronbach's alpha] and 0.87-0.90 [intraclass correlation]). ASI/ASUI 
      scores correlated strongly with ACQ-5 and SGRQ scores (spearman correlation 
      [r(s)] magnitude: 0.67-0.85). ASI and ASUI scores differed for asthma control 
      (defined by ACQ-5) and lung function (% predicted forced expiratory volume in 1 
      second). Changes in ASI and ASUI scores from baseline to week 4 and week 12 had 
      high correlations with changes in ACQ-5 (r(s) magnitude: 0.57-0.69). MCIDs ranged 
      from -0.42 to -0.26 (ASI) and 0.07 to 0.11 (ASUI). CONCLUSION: Findings show the 
      good reliability, validity, and responsiveness of the ASI, indicating potential 
      value for real-world symptom assessment in severe asthma.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Shen, Qin
AU  - Shen Q
AD  - Value Evidence and Outcomes, GSK, Collegeville, Pa.
FAU - von Maltzahn, Robyn
AU  - von Maltzahn R
AD  - Value Evidence and Outcomes, GSK, Uxbridge, Middlesex, United Kingdom.
FAU - Nelsen, Linda
AU  - Nelsen L
AD  - Value Evidence and Outcomes, GSK, Collegeville, Pa.
FAU - Revicki, Dennis
AU  - Revicki D
AD  - Revicki Outcomes Research Consulting, Sarasota, Fla. Electronic address: 
      dennis.revicki@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200824
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
SB  - IM
MH  - *Asthma/diagnosis
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Psychometrics
MH  - Quality of Life
MH  - Reproducibility of Results
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Asthma
OT  - Asthma Symptom Index
OT  - Asthma Symptom Utility Index
OT  - Minimum clinically important difference
OT  - Patient-reported outcomes
OT  - Psychometrics
OT  - Reliability
OT  - Validity
EDAT- 2020/08/28 06:00
MHDA- 2021/05/22 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/03/11 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - S2213-2198(20)30835-7 [pii]
AID - 10.1016/j.jaip.2020.08.019 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2021 Jan;9(1):400-409.e1. doi: 
      10.1016/j.jaip.2020.08.019. Epub 2020 Aug 24.